EUVIMEDEUVIMED entdecken
Open Access

Depleting HIF‑1α attenuates the progression of osteosarcoma, but tumorigenicity is sustained through HIF‑independent pathways

Ayaka Kunishima, Takatsune Shimizu, Tetsuya Takimoto, Atsunobu Sagara, Hiroyuki Nobusue, Hidetoshi Hasuwa, Shinya Hasegawa, Yuka Tamaoki, Hitomi Miyake, Yumi Fukuchi, Hideyuki Saya, Akihiro Muto

Oncology Reports · 12.03.2026 · 55 (5) · 1-14

DOI: 10.3892/or.2026.9099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Reports, online erschienen am 12.03.2026. Verfasst von Ayaka Kunishima und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan. Hauptthemen laut MEDLINE: Osteosarcoma, Hypoxia-Inducible Factor 1, alpha Subunit, Bone Neoplasms. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaHypoxia-Inducible Factor 1, alpha SubunitBone NeoplasmsAnimalsMiceHumansCell ProliferationSignal TransductionCell Line, TumorGene Expression Regulation, NeoplasticDisease ProgressionGlycolysisTOR Serine-Threonine KinasesMice, Inbred C57BLCarcinogenesis

Stichwörter der Autor:innen

hypoxia inducible factor‑1osteosarcomatumor heterogeneity

Substanzen

Hypoxia-Inducible Factor 1, alpha SubunitTOR Serine-Threonine KinasesHIF1A protein, humanHif1a protein, mouse

Autor:innen und Institutionen

  • Department of Pathophysiology, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan.
  • Department of Data Science, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake, Aichi 470‑1192, Japan.
  • Department of Pharmacy, Japanese Red Cross Medical Center, Shibuya, Tokyo 150‑8935, Japan.
  • Department of Gene Regulation, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake, Aichi 470‑1192, Japan.
  • Department of Collaborative Research Resources (Laboratory Animal Center), Keio University School of Medicine, Shinjuku, Tokyo 160‑8582, Japan.
  • Department of Environmental Health Sciences, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142‑8501, Japan.

Zitieren

APA

Kunishima, A., Shimizu, T., Takimoto, T., Sagara, A., Nobusue, H., Hasuwa, H., Hasegawa, S., Tamaoki, Y., Miyake, H., Fukuchi, Y., Saya, H., & Muto, A. (2026). Depleting HIF‑1α attenuates the progression of osteosarcoma, but tumorigenicity is sustained through HIF‑independent pathways. Oncology Reports, 55(5), 1-14. https://doi.org/10.3892/or.2026.9099

Vancouver

Kunishima A, Shimizu T, Takimoto T, Sagara A, Nobusue H, Hasuwa H, et al. Depleting HIF‑1α attenuates the progression of osteosarcoma, but tumorigenicity is sustained through HIF‑independent pathways. Oncology Reports. 2026;55(5):1-14. doi:10.3892/or.2026.9099

BibTeX
@article{Kunishima2026,
  author = {Kunishima, Ayaka and Shimizu, Takatsune and Takimoto, Tetsuya and Sagara, Atsunobu and Nobusue, Hiroyuki and Hasuwa, Hidetoshi and Hasegawa, Shinya and Tamaoki, Yuka and Miyake, Hitomi and Fukuchi, Yumi and Saya, Hideyuki and Muto, Akihiro},
  title = {Depleting HIF‑1α attenuates the progression of osteosarcoma, but tumorigenicity is sustained through HIF‑independent pathways},
  journal = {Oncology Reports},
  year = {2026},
  volume = {55},
  number = {5},
  pages = {1--14},
  doi = {10.3892/or.2026.9099}
}
Kostenlos starten →